Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

10x Genomics (TXG) Shares Outstanding (2018 - 2026)

10x Genomics' Shares Outstanding history spans 8 years, with the latest figure at $127.7 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 4.42% to $127.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $127.7 million, a 4.42% increase, with the full-year FY2025 number at $127.7 million, up 4.42% from a year prior.
  • Shares Outstanding hit $127.7 million in Q4 2025 for 10x Genomics, up from $126.5 million in the prior quarter.
  • Over the last five years, Shares Outstanding for TXG hit a ceiling of $127.7 million in Q4 2025 and a floor of $109.6 million in Q1 2021.
  • Historically, Shares Outstanding has averaged $117.9 million across 5 years, with a median of $117.8 million in 2023.
  • Biggest five-year swings in Shares Outstanding: rose 11.66% in 2021 and later increased 2.38% in 2022.
  • Tracing TXG's Shares Outstanding over 5 years: stood at $112.5 million in 2021, then grew by 2.38% to $115.2 million in 2022, then rose by 3.39% to $119.1 million in 2023, then grew by 2.68% to $122.3 million in 2024, then increased by 4.42% to $127.7 million in 2025.
  • Business Quant data shows Shares Outstanding for TXG at $127.7 million in Q4 2025, $126.5 million in Q3 2025, and $124.4 million in Q2 2025.